Shoppers aren’t imagining it: Luxury goods cost a lot more these days, with no improvement in quality to make up for it. Weak ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Novo Nordisk (NVO) has released an update. Novo Nordisk, a leading global healthcare company, recently reported that its board members and ...

Novo Nordisk ( (NVO) ) has released its Q3 earnings. Here is a breakdown of the information Novo Nordisk presented to its investors. Novo ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Novo Nordisk remains a sell due to increased competition and regulatory risks, despite its leadership in the diabetes and weight-loss markets. Hims & Hers anticipates selling a generic version of ...

even their letter O sometimes comes slashed in half. But, Denmark is also home to what is suddenly Europe's largest company—Novo Nordisk…. a pharmaceutical firm with a market cap of a half ...

Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like peptide receptor agonist (GLP-1RA).